Figure 6. TP15-Fc prevents tumor engraftment in the INA-6.
Tu1 xenograft model. (A) 48h after i.p. inoculation of 2.5×107 INA-6.Tu1 cells in SCID/beige mice, mice were treated twice weekly either with vehicle (PBS control; dotted black line), 4D5-Fc (grey line) and TP15-Fc (black line), respectively. All mice received seven single doses (cumulative treatment dose: 1150 μg) by i.p. injection. Compared to the control mice (ten PBS and five 4D5-Fc-treated animals), which needed to be sacrificed within 55 days after tumor cell inoculation, INA-6.Tu1 cells did not engraft in the TP15-Fc-treated mice within 120 days (p < 0.001). ↓ = time point of i.p. injection. (B) Graph shows the human interleukin 6 receptor (huIL-6R) concentration in final sera of 5 mice per group measured by ELISA.